The European Agency for the Evaluation of Medicinal Products
Press office

London, 1 April 2004
Doc. Ref: EMEA/D/9254/04

Press release
EMEA launches EudraVigilance training programme

The EMEA today announced the launch of a large-scale user-training programme for EudraVigilance. The programme will begin in May 2004.

EudraVigilance is the European pharmacovigilance data-processing network and management system. It enables rapid and efficient electronic transmission of adverse reaction data. Business partners in this exchange are the EMEA, national competent authorities (including the 10 new EU Member States) and the pharmaceutical industry.

The EudraVigilance training programme aims to provide participants with the skills and competencies required to efficiently manage the new concepts of electronic reporting in the European Economic Area. This training programme has been elaborated in collaboration with Drug Information Association[1], which will act as a conference organiser.

From May 2004, regular training sessions will take place at the EMEA. Upon completion of a two and a half days course, participants will receive a user certificate. The course is open to regulators and pharmaceutical companies in the enlarged European Union. It will also be open to academic sponsors following the implementation of the Clinical Trials Directive[2].

For details about the objectives of the training course, who should attend, prerequisites, courses schedule and fees, please visit http://eudravigilance.emea.eu.int.

--END--

NOTES:

1. The Drug Information Association (DIA) is a not-for-profit organisation. Further details about the Association can be found at http://www.diahome.org
2. Directive 2001/20/EC of the European Parliament and of the Council of 4 April 2001 on the approximation of the laws, regulations and administrative provisions of the Member States relating to the implementation of good clinical practice in the conduct of clinical trials on medicinal products for human use (OJ L 121, 1.5.2001, p. 34).

General enquiries to:
Noel Wathion, Head of Unit, Post-authorisation evaluation of medicines for human use
Tel. (44-20) 74 18 85 92, E-mail: noel.wathion@emea.eu.int

Media enquiries to:
Martin Harvey Allchurch, EMEA press officer
Tel. (44-20) 74 18 84 27, E-mail: press@emea.eu.int